Increased expression of TNF ligand‑related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis

Zhang,Erwei; Zhu,Xuhui; Han,Song; Peng,Zhifeng; Wang,Wei; Li,Junfa; Yang,Yong

doi:10.3892/etm.2012.778

Increased expression of TNF ligand‑related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis

Authors:
- Erwei Zhang
- Xuhui Zhu
- Song Han
- Zhifeng Peng
- Wei Wang
- Junfa Li
- Yong Yang
View Affiliations

Affiliations: Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Neurobiology and Beijing Institute for Neuroscience, Capital Medical University, Beijing 100069, P.R. China
Published online on: October 30, 2012 https://doi.org/10.3892/etm.2012.778
Pages: 282-286

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Members of the tumor necrosis factor (TNF) superfamily have been revealed to be associated with painful bladder syndrome/interstitial cystitis (PBS/IC). TNF ligand‑related molecule 1A (TL1A) and its receptor, death receptor 3 (DR3), belong to the TNF superfamily and have been implicated in chronic inflammatory diseases. Bladder biopsies from 8 female patients clinically diagnosed with PBS/IC according to the National Institute for Diabetes and Digestive and Kidney Diseases criteria and 8 female bladder carcinoma control patients were investigated to test the protein and mRNA expression levels of TL1A and DR3 using western blotting and real‑time RT‑PCR. The protein level ratio of TL1A to β‑actin (IC, 0.65±0.03 vs. controls, 0.25±0.02, P<0.001) and of its receptor DR3 to β‑actin (IC, 0.66±0.06 vs. controls, 0.27±0.02, P<0.001) were observed to be significantly higher in the patients with IC. The real‑time RT‑PCR ∆Cts of TL1A minus GAPDH (IC, 7.60±0.52 vs. controls, 10.08±0.32, P<0.001) and the DR3 minus GAPDH (IC, 6.68±0.60 vs. controls, 8.99±0.61, P=0.017) were observed to be significantly lower in the patients with IC, suggesting that the mRNA levels of TL1A and DR3 were higher in the PBS/IC patients. The protein and mRNA expression of TL1A and DR3 are upregulated in the bladder tissues of PBS/IC patients and may be involved in inflammation and apoptosis in PBS/IC.

View Figures

View References

1	Clemens JQ, Meenan RT, Rosetti MC, Gao SY and Calhoun EA: Prevalence and incidence of interstitial cystitis in a managed care population. J Urol. 173:98–102. 2005. View Article : Google Scholar : PubMed/NCBI
2	Choe JH, Son H, Song YS, Kim JC, Lee JZ and Lee KS: Prevalence of painful bladder syndrome/interstitial cystitis-like symptoms in women: A population-based study in Korea. World J Urol. 29:103–108. 2011. View Article : Google Scholar : PubMed/NCBI
3	Wang ZY and Bjorling DE: Tumour necrosis factor-α induces expression and release of interleukin-6 by human urothelial cells. Inflammation Res. 60:525–532. 2011.
4	Imamura T, Igawa Y, Ogawa T, Homma T, Seki S, Ishizuka O, Satoshi A, Homma Y and Nishizawa O: Expression level of CXCL10 peptide in bladder urothelium and urine as possible biomarkers for diagnosis of ulcerative interstitial cystitis. Eur Urol Suppl. 9:2122010. View Article : Google Scholar
5	Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T and Hansen AB: YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology. 57:371–383. 2010. View Article : Google Scholar
6	Ogawa T, Homma T, Igawa Y, Seki S, Ishizuka O, Imamura T, Akahane S, Homma Y and Nishizawa O: CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 183:1206–1212. 2010. View Article : Google Scholar : PubMed/NCBI
7	Lv J, Luo Y, Leng J, Xue W, Liu D and Huang Y: Aberrant expression of monocyte chemoattractant protein-1 (mcp-1) in interstitial cystitis patients. Sci Res Essays. 5:663–667. 2010.
8	Kutlu O, Akkaya E, Koksal IT, Bassorgun IC, Ciftcioglu MA, Sanlioglu S and Kukul E: Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis. Int Urol Nephrol. 42:393–399. 2010. View Article : Google Scholar : PubMed/NCBI
9	Chen MC, Keshavan P, Gregory GD and Klumpp DJ: RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am J Physiol Renal Physiol. 292:F1372–F1379. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zhang N, Sanders AJ, Ye L, Kynaston HG and Jiang WG: Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res. 30:87–95. 2010.PubMed/NCBI
11	Song YJ, Meylan F, Botson J, Goldbach-Mansky R, Lee D and Siegel R: TL1A-DR3 interactions are important in both adaptive and innate immunity in inflammatory arthritis. Clin Immunol. 135:S882010. View Article : Google Scholar
12	Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G and Truneh A: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 204:35–46. 1997. View Article : Google Scholar : PubMed/NCBI
13	Gillenwater JY and Wein AJ: Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol. 140:203–206. 1988.PubMed/NCBI
14	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
15	Taraban VY, Slebioda TJ, Willoughby JE, Buchan SL, James S, Sheth B, Smyth NR, Thomas GJ, Wang EC and Al-Shamkhani A: Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol. 4:186–196. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pobezinskaya YL, Choksi S, Morgan MJ, Cao X and Liu ZG: The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling. J Immunol. 186:5212–5216. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kang YJ, Kim WJ, Bae HU, Kim DI, Park YB, Park JE, Kwon BS and Lee WH: Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine. 29:229–235. 2005. View Article : Google Scholar : PubMed/NCBI
18	Young HA and Tovey MG: TL1A: a mediator of gut inflammation. Proc Natl Acad Sci USA. 103:8303–8304. 2006. View Article : Google Scholar : PubMed/NCBI
19	Altamirano CV, Pang S, Li LY and Berenson JR: Vascular endothelial growth inhibitor (vegi) inhibits the growth of multiple myeloma plasma cells and induces their apoptosis. Blood. 98:638A2001.
20	Abdel-Mageed AB and Ghoniem GM: Potential role of rel/nuclear factor-kappaB in the pathogenesis of interstitial cystitis. J Urol. 160:2000–2003. 1998. View Article : Google Scholar : PubMed/NCBI
21	Yamada T, Nishimura M and Mita H: Increased number of apoptotic endothelial cells in bladder of interstitial cystitis patients. World J Urol. 25:407–413. 2007. View Article : Google Scholar : PubMed/NCBI
22	Hsieh JH, Chen CY and Kuo HC: Increased apoptosis and decreased junction protein expression of urothelium due to suburothelial inflammation in patients with interstitial cystitis/painful bladder syndrome. Neurourol Urodynamics. 29:1138–1140. 2010.
23	Shie JH, Liu HT and Kuo HC: Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 79:484 e7–e13. 2012.
24	Wang W, Zhang N, Zhu XH, He ZS, Wahafu W, Xu ZQ and Yang Y: Involvement of TL1A and DR3 in induction of ischaemia and inflammation in urinary bladder dysfunction in the elderly. Mol Med Rep. 6:434–438. 2012.PubMed/NCBI
25	Wang L, Pan W, Zhu FL, Jiao BH, Lou YH, Xiao Y and Qi ZT: Cloning, expression and biological activity of VEGI(151), a novel vascular endothelial cell growth inhibitor. Acta Biochimica Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 32:485–489. 2000.PubMed/NCBI
26	Chen X, Wu JH, Liu HN, He Z, Gu M, Wang N, Ma J, Hu J, Xia L, He H, Yuan J, Li J, Li L, Li M and Zhu X: Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci. 19:449–457. 2010.PubMed/NCBI
27	Pontari MA, Hanno PM and Ruggieri MR: Comparison of bladder blood flow in patients with and without interstitial cystitis. J Urol. 162:330–334. 1999. View Article : Google Scholar : PubMed/NCBI
28	Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, Qin J, Li X and Tuohy VK: Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol. 61:193–200. 2012. View Article : Google Scholar : PubMed/NCBI
29	Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg L Jr, Payne CK, Wesselmann U and Faraday MM; Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research Inc: AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 185:2162–2170. 2011. View Article : Google Scholar